Clinical trials: Collaborative Skills
COVID-19, SARS-CoV2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19).
- Trial name
- BLAZE-2 (NCT04497987)
- Testing
- Bamlanivimab, Etesevimab
- Where
- 27 sites in United States
- Volunteers
- 1,180 people
- Sponsor
- Eli Lilly and Company